Cost-effectiveness of prophylaxis and treatment of influenza;Kosteneffektivität der Prophylaxe und Behandlung von Influenza

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 43, 2003, Pages 2267-2270

  Rychlik, R ^a   Heinen Kammerer, T ^a   Rusche, H ^b   Piercy, J ^e   Scuffham, P ^c   Zollner Y ^d  

^a Inst Empirische Gesundheitsokonomie   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF YORK   (United Kingdom)

^d Solvay Pharmaceuticals GmbH   (Germany)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ADULT; AGED; ANTIBIOTIC THERAPY; CONSULTATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; GERMANY; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; LITERATURE; MAJOR CLINICAL STUDY; MEDLINE; MODEL; MORTALITY; NONHUMAN; NOTE; PUBLICATION; QUESTIONNAIRE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0242301717     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43100     Document Type: Note

References (21)

1. AGI Arbeitsgemeinschaft Influenza. Abschlussbericht der Influenzasaison 2001/02. Berlin, 2002
2. Deutsche Krankenhausgesellschaft (DKG), 1999
3. Fock R, Bergmann H, Bußmann H et al. Management und Kontrolle einer Influenzapandemie. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2001; 44: 969-980
4. Glathe H, Lange W. Influenza vaccination in older patients. Drug & Aging 1996; 5: 368-387
5. Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. JAMA 1993; 272: 1661-1665
6. Hallauer JF, Ronde M. Gesundheitliche und ökonomische Auswirkungen der Influenza und Influenza-Schutzimpfung. Immunologie & Impfen 1999; 2: 140-145
7. Kressin BW, Hallauer JF, Influenza: Ökonomische Bedeutung der Schutzimpfung. Dtsch Ärztebl 1999; 96: A-342
8. Mauskopf JA, Cates SC, Griffin AD. A Pharmacoeconomic model for the treatment of Influenza. Pharmacoeconomics 1999; 16 (Suppl 1); 73-84
9. NICE: . Guidance on the use of zanamivir (Relenza) in the treatment of influenza. National Institute for Clinical Excellence; London, 2000
10. NICE . Fast Track Appraisal of Zanamivir (Relenza): Summary of Evidence, National Institute for Clinical Excellence; London, 2000
11. NICE: . Appraisal Consultation Document: The clinical and cost effectiveness of zanamivir, oseltamivir and amantadine for the treatment and prophylaxis of influenza. National Institute for Clinical Excellence; London, 2000
12. Nichol K, Goodman M. The health and economic benefit of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. PharmacoEconomics 1999; 16: 63-71
13. OECD . Development cooperation report 1998. Paris, OECD, 1999
14. Postma MJ, Heijnen MLA, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for eldery individuals in the Netherlands. PharmacoEconomics 2001; 19: 215-222
15. Robert Koch-Institut. Epidemiologisches Bulletin; 19. April 2002; 16
16. Robert Koch-Institut. Epidemiologisches Bulletin; 20. September 2002; 38
17. Schwabe U, Paffrath D. Arzneiverordnungs-Report, 2000
18. Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. PharmacoEconomics 1996; 9: 51-60(Suppl 1
19. Scuffham PA, Posnett JW, West PA. Health economics in decision making for influenza management, World Congress on Options for the Control of Influenza IV, in: Osterhaus, A.D.M.E.; Cox, N.; Hampson, A.W. 2001: 81-85
20. Szucs TD. Influenza - The Role of Burden-of-Illness Research. Pharmacoeconomics 1999; 1: 27-32
21. Von der Arbeitsgemeinschaft Influenza, dem Hygienischen Institut, Universitäten Wuppertal, Mainz, Erlangen, Tübingen, Würzburg.